8-K: Verastem Exercises Option for Novel KRAS G12D Inhibitor and Prepares for Potential LGSOC Treatment Launch

Verastem, Inc. has exercised its option to acquire rights to a novel KRAS G12D inhibitor and is preparing for a potential mid-2025 launch of its avutometinib and defactinib combination for recurrent KRAS mutant Low-Grade Serous Ovarian Cancer (LGSOC).

Summary

• Verastem has exercised its option with GenFleet for VS-7375, a KRAS G12D inhibitor, and plans to file a U.S. IND in Q1 2025 and initiate a Phase 1/2a trial in mid-2025.
• The company is focused on the potential mid-2025 launch of avutometinib and defactinib for recurrent KRAS mutant LGSOC, with a PDUFA action date of June 30, 2025.
• The combination therapy demonstrated a 44% objective response rate (ORR) in KRAS mutant LGSOC patients and a 31% ORR overall in the RAMP 201 trial.
• The median progression-free survival (PFS) was 22 months in KRAS mutant patients and 12.9 months overall.
• Verastem is also exploring the combination in first-line metastatic pancreatic cancer (RAMP 205) and advanced lung cancer (RAMP 203).
• The company has $113.2 million in cash, cash equivalents, and short-term investments as of September 30, 2024, and a pro-forma balance of $128.6 million as of December 31, 2024, including recent financing.
• A $25 million tranche of a credit facility is available upon FDA approval of the LGSOC treatment, and a further $50 million is available upon achieving $55 million in trailing six-month revenue.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising clinical trial results, a clear regulatory path, and a focused commercialization strategy. The exercise of the GenFleet option and the availability of non-dilutive capital further enhance the positive sentiment. However, there are some risks and challenges that temper the overall sentiment.

Positives

• The exercise of the GenFleet option for VS-7375 provides a potential best-in-class KRAS G12D inhibitor.
• The avutometinib and defactinib combination has shown promising efficacy and tolerability in LGSOC, with a clear regulatory path.
• The company has a focused launch model for the LGSOC treatment, targeting a significant market opportunity.
• The RAMP 201 trial data supports the combination's potential as a new standard of care for recurrent KRAS mutant LGSOC.
• The company has multiple ongoing clinical trials to expand the use of avutometinib and defactinib into other cancer types.
• Verastem has secured non-dilutive capital through a credit facility, providing financial flexibility.

Negatives

• The document highlights that monotherapy with avutometinib showed a lower response rate compared to the combination therapy.
• The low-dose regimen of avutometinib and defactinib was determined to be suboptimal based on disease progression rates.
• The company is reliant on third-party contract research organizations and manufacturing organizations, which could pose risks.
• There is a risk that the market opportunities for the drug candidates may be smaller than currently estimated.
• The company faces substantial competition in the oncology space, which could impact market share.

Risks

• The success of the product candidates is subject to the uncertainties inherent in research and development, including unexpected clinical trial results.
• Regulatory approvals are not guaranteed, and there is a risk that the FDA may require additional studies or data.
• The company may face challenges in obtaining and maintaining patent protection for its product candidates.
• There are risks associated with the timing, scope, and rate of reimbursement for the product candidates.
• The company may not have sufficient cash to fund its operations and may need to raise additional capital.
• There is a risk that third-party partners may fail to fully perform under agreements.

Future Outlook

Verastem anticipates a potential mid-2025 launch of avutometinib and defactinib for recurrent KRAS mutant LGSOC, and is focused on expanding the use of the combination into other cancer types. The company also expects to advance its collaboration with GenFleet and progress the development of VS-7375.

Management Comments

• Management believes non-GAAP information is useful for investors as it provides greater transparency and period-over-period comparability.
• Management uses non-GAAP measures to assess and analyze operational results and trends and to make financial and operational decisions.

Industry Context

The document highlights the significant unmet need for effective treatments in RAS/MAPK pathway-driven cancers, particularly LGSOC. The company's focus on developing novel therapies for these cancers aligns with the broader industry trend of targeting specific genetic mutations to improve patient outcomes. The collaboration with GenFleet also reflects the industry's increasing interest in partnerships to accelerate drug development.

Comparison to Industry Standards

• The RAMP 201 trial results for avutometinib and defactinib in LGSOC show a 44% ORR in KRAS mutant patients, which is significantly higher than the 6-13% ORR seen with standard of care treatments like chemotherapy and hormonal therapy as shown in the GOG 281 and MILO studies.
• The median PFS of 22 months in KRAS mutant patients is also a notable improvement compared to the PFS of 7.2-13 months reported in the GOG 281 and MILO studies for standard of care and MEK inhibitors.
• The discontinuation rate due to adverse events for the combination therapy was 10%, which is lower than the 17-36% discontinuation rates reported in the GOG 281 and MILO studies for standard of care and MEK inhibitors.
• The document compares the results of the RAMP 205 trial in pancreatic cancer to the MPACT, NAPOLI 3 and PRODIGE trials, which are landmark trials in first-line metastatic pancreatic cancer. The RAMP 205 trial is showing an encouraging early ORR of 83% in the first dose level, which is higher than the 23-36% ORR reported in the comparator arms of the landmark trials.
• The document compares the preclinical properties of VS-7375 to other KRAS G12D inhibitors from companies such as Mirati, RevMed, Lilly, AstraZeneca, Incyte, Quanta, Tyligand, Betta and Hengrui. VS-7375 shows a better ON/OFF selectivity ratio, oral availability, and tumor regression in preclinical models.

Stakeholder Impact

• Shareholders may benefit from the potential commercial success of the LGSOC treatment and the expansion into other cancer types.
• Employees may benefit from the company's growth and success.
• Patients with LGSOC and other cancers may benefit from new treatment options.
• Customers (healthcare providers) may benefit from new treatment options for their patients.
• Suppliers and creditors may benefit from the company's financial stability and growth.

Next Steps

• Complete enrollment in RAMP 301 by the end of 2025.
• Report initial data from the RAMP 201J Phase 2 clinical trial in Japan in H2 2025.
• Publish RAMP 201 primary analysis and submit for NCCN consideration in H1 2025.
• Present additional analyses from the RAMP 201 trial at a medical meeting in Q1 2025.
• Determine RP2D for expansion cohort in RAMP 205 in H1 2025.
• Present data from RAMP 205 at a medical meeting in mid-2025.
• Complete enrollment in the KRAS G12C inhibitor prior-treated Stage 1 Part B doublet cohort in RAMP 203 in Q1 2025.
• Complete enrollment and evaluate the safety and efficacy of the triplet combination in RAMP 203 in H1 2025.
• Present an interim update from RAMP 203 at a medical meeting in H2 2025.
• File U.S. IND for VS-7375 during Q1 2025 and initiate a Phase 1/2a study in mid-2025.

Key Dates

Keywords

KRAS G12D inhibitor, avutometinib, defactinib, LGSOC, oncology, RAS/MAPK pathway, pancreatic cancer, lung cancer, clinical trials, FDA approval